Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: J Autoimmun. 2019 May 9;102:65–76. doi: 10.1016/j.jaut.2019.04.017

Figure 3: Systemic and local neutralization of IL-22 levels during adaptive phase increases EAU severity.

Figure 3:

C57BL/6J mice were immunized with IRBP and were treated systemically or locally with IL-22 neutralizing antibody. (A) Mice treated systemically with anti-IL-22 neutralizing antibody had significantly higher disease than the controls. 500μg of anti-mouse IL-22 (clone 8E11) or its isotype control antibodies were given intraperitoneally on days 7, 9, 11, 13, and 15 post-immunization. Data shown are average disease scores of individual mouse eyes on day 21. Results were pooled from two separate experiments and were analyzed by Mann-Whitney U method (p = 0.05). (B) Mice treated locally with anti-IL-22 neutralizing antibody had significantly higher disease than the controls. Each eye was injected intravitreally with either anti-mouse IL-22 or its isotype control antibodies (7μg antibody in 2μl/eye) on day 8 after uveitogenic immunization. Result from one out of three similar experiments is shown below. Data were analyzed by Mann-Whitney U method (p = 0.01).